PMID: 9420033Jan 7, 1998Paper

Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration

Antimicrobial Agents and Chemotherapy
I TegederG Geisslinger

Abstract

The pharmacokinetics of imipenem-cilastatin were investigated in 12 critically ill patients with acute renal failure (ARF) managed by continuous veno-venous hemofiltration (CVVH) while receiving a fixed combination of 500 mg of imipenem-cilastatin intravenously three or four times daily. No adverse drug reactions were observed. Plasma and hemofiltrate samples were taken at specified times during one dosing interval, and the concentrations of imipenem and cilastatin were determined by high-performance liquid chromatography. Pharmacokinetic variables were calculated by a first-order, two-compartment pharmacokinetic model for both substances. Total clearances of imipenem and cilastatin (mean +/- standard deviations) were 122.2 +/- 28.6 and 29.2 +/- 13.7 ml/min, respectively, with hemofiltration clearances of 22.9 +/- 2.5 and 16.1 +/- 3.1 ml/min, respectively, and nonrenal, nonhemofiltration clearances of 90.8 +/- 26.3 and 13.2 +/- 13.9 ml/min, respectively. Mean imipenem dosage requirements were approximately 2,000 mg/24 h (2,111.8 +/- 493.4 mg/24 h). They were calculated in order to achieve an average steady-state concentration of 12 mg/liter to ensure that concentrations in plasma exceeded the MICs at which 90% of intermediately...Continue Reading

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Mar 1, 1992·Clinical Pharmacokinetics·W L St PeterC E Halstenson
Jan 1, 1991·Contributions to Nephrology·M PrzecheraT Risler
Aug 1, 1991·Antimicrobial Agents and Chemotherapy·K KonishiA Hisaka
Jul 1, 1990·The Journal of Antimicrobial Chemotherapy·A A AlarabiB Wikström
Aug 1, 1990·Journal of Pharmaceutical Sciences·G B SmithA W Douglas
Sep 1, 1988·Journal of Pharmaceutical Sciences·B P ImbimboG Bassotti
Nov 1, 1988·Clinical Pharmacokinetics·W M Bennett
Dec 1, 1986·The Journal of Antimicrobial Chemotherapy·R G FinchN B Deaney
Jul 1, 1986·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·T P Gibson
Jun 7, 1985·The American Journal of Medicine·G L Drusano, H C Standiford
Jun 7, 1985·The American Journal of Medicine·T P GibsonJ A Bland
Sep 25, 1971·Lancet·R W Jelliffe, S M Jelliffe
Dec 1, 1983·The Journal of Antimicrobial Chemotherapy·F M KahanJ Birnbaum
Oct 1, 1984·European Journal of Clinical Microbiology·I Braveny
Jul 1, 1984·Antimicrobial Agents and Chemotherapy·C M Myers, J L Blumer
Nov 1, 1984·Antimicrobial Agents and Chemotherapy·S R NorrbyJ Y Hsieh
Feb 1, 1993·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·B A MuellerW L Macias

❮ Previous
Next ❯

Citations

Oct 6, 2000·Clinical Pharmacokinetics·J W MoutonA A Vinks
Mar 20, 2014·Medizinische Klinik, Intensivmedizin und Notfallmedizin·R Bellmann
Oct 19, 2014·Journal of Intensive Care Medicine·Susan J Lewis, Bruce A Mueller
Apr 1, 2020·Archives of Physiology and Biochemistry·Nisha SharmaAnil Bhanudas Gaikwad
May 27, 2005·Antimicrobial Agents and Chemotherapy·Douglas N FishEdward Abraham
Jun 3, 2009·Critical Care Medicine·Gordon ChoiJeffrey Lipman
Dec 13, 2005·Pharmacy World & Science : PWS·Alison CottonAlison Holmes
Feb 13, 2020·Pharmacy : Journal of Pharmacy, Education and Practice·Soo Min JangAmir Abdi Pour
Oct 3, 2002·Current Opinion in Critical Care·John Goldberg, Robert C Owens
Sep 16, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robin L TrotmanWilliam L Salzer
Feb 26, 2013·Journal of Chemotherapy·Dominique BreilhEmmanuel Boselli
Sep 16, 1998·Antimicrobial Agents and Chemotherapy·F ThalhammerK Ratheiser
Aug 28, 2003·Artificial Organs·Bruce A MuellerKevin M Sowinski
May 4, 2021·Seminars in Dialysis·Soo Min Jang, Linda Awdishu
Nov 19, 2021·The Journal of Antimicrobial Chemotherapy·Kim DaoMonia Guidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
B A MuellerW L Macias
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
E KellerP Schollmeyer
Zhonghua wai ke za zhi [Chinese journal of surgery]
Xin-ya TangJie-shou Li
© 2021 Meta ULC. All rights reserved